Skip to content

Net margin at other companies

Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
29.6%-2.3pp
Bausch + Lomb logo
Bausch + LombBLCO
-4.2%-1.3pp
HRO
HarrowHROW
-19.8%+18.0pp
Tarsus Pharmaceuticals, Inc. logo
Tarsus Pharmaceuticals, Inc.TARS
-9%-4.0pp
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
-90.9%-2.1pp
PBH
Prestige Consumer HealthcarePBH
17.5%-1.4pp

Other financials

Income statement

See full
Revenue$10.8M+0.8%
Gross profit$9.5M+0.2%
Operating income-$93.3M-46.0%
Net income-$88.6M-38.3%
EPS (diluted)-$0.40-5.3%

Balance sheet

See full
Cash & equivalents$666.7M+90.7%
Total debt$79.5M+4.2%
Total equity$581.6M+119%
Total assets$732.5M+80.5%

Cash flow

See full
Operating cash flow-$66.0M-47.7%
CapEx$4.7M+141%
Free cash flow-$70.7M-51.6%

Valuation

See full
Market cap$2.21B+58.2%
Enterprise value$1.63B+40.8%
P/S42.6×+19.1×

Profitability

See full
Gross margin87.2%-3.4pp
Operating margin-575.4%+1,233pp
FCF margin-463%+2,860pp

Returns & leverage

See full
Return on equity-68.6%+17.0pp
Debt / equity0.1×-0.2×
Current ratio14.8×+4.6×

Where this comes from

Calculated from Ocular Therapeutix’s reported figures.

Based on trailing twelve months.

The official record: Ocular Therapeutix’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Ocular Therapeutix's net margin.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Ocular Therapeutix's net margin?
Ocular Therapeutix (OCUL) reported net margin of -558.2% in Q1 2026.
How has Ocular Therapeutix's net margin changed year-over-year?
Ocular Therapeutix's net margin decreased by 72.8% year-over-year, from -323.1% to -558.2%.
What is the long-term trend for Ocular Therapeutix's net margin?
Over 5 years (2020 to 2025), Ocular Therapeutix's net margin has grown at a -10.6% compound annual growth rate (CAGR), from -894.3% to -511.9%.
What does net margin mean?
Net income as a percentage of revenue (trailing twelve months). The bottom-line profitability measure after all costs, interest, and taxes.